16 articles for W Chang
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
2'-deoxy-2'-a-fluoro-2'-ß-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938.

Pharmasset
Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation.

Purdue University
Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic.

TBA
Structure-Based Optimization of Novel Sterol 24-C-Methyltransferase Inhibitors for the Treatment of Candida albicans Infections.

Shandong University
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.

Merck
Design and synthesis of ether analogues as potent and selective M2 muscarinic receptor antagonists.

Schering-Plough Research Institute
Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.

Genentech
Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide.

Shandong University
Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain

Inserm (Institut National De La Sante Et De La Recherche Medicale)
Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof

Shanghai Ennovabio Pharmaceuticals
Imidazopyridazine and imidazopyridine compounds and uses thereof

Incyte
Cyclic compound having dopamine D3 receptor antagonistic effect

Shionogi
Heterocyclic compounds and uses thereof

Incyte
Pyrimidine derivative

Aska Pharmaceutical
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.

Pharmacia Italia
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3.

Bristol-Myers Squibb